Profile data is unavailable for this security.
About the company
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
- Revenue in USD (TTM)27.69k
- Net income in USD-17.46m
- Incorporated2005
- Employees21.00
- LocationDare Bioscience Inc3655 Nobel Dr Ste 260SAN DIEGO 92122-1050United StatesUSA
- Phone+1 (858) 926-7655
- Fax+1 (302) 636-5454
- Websitehttps://www.darebioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cellectar Biosciences Inc | 0.00 | -18.85m | 13.95m | 11.00 | -- | 1.40 | -- | -- | -10.78 | -10.78 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -72.62 | -104.57 | -141.24 | -133.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.23 | -- | 33.54 | -- |
| Lexaria Bioscience Corp | 522.00k | -10.79m | 15.49m | 7.00 | -- | 2.82 | -- | 29.68 | -0.5743 | -0.5743 | 0.0272 | 0.221 | 0.0659 | -- | 2.97 | 74,571.43 | -136.35 | -102.60 | -145.39 | -105.78 | 100.00 | 87.95 | -2,069.41 | -1,579.38 | -- | -285.30 | 0.00 | -- | 52.05 | 17.53 | -105.37 | -- | 48.50 | -- |
| Hoth Therapeutics Inc | 0.00 | -12.16m | 15.82m | 2.00 | -- | 1.87 | -- | -- | -1.06 | -1.06 | 0.00 | 0.5442 | 0.00 | -- | -- | 0.00 | -138.61 | -129.47 | -154.67 | -144.30 | -- | -- | -- | -- | -- | -493.48 | 0.00 | -- | -- | -- | -4.37 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 26.85m | -49.38m | 17.47m | 233.00 | -- | -- | -- | 0.6506 | -2.98 | -2.98 | 1.62 | -1.85 | 0.6096 | 1.60 | 4.22 | 115,218.90 | -107.02 | -36.27 | -277.91 | -51.90 | 53.68 | 57.36 | -175.56 | -124.01 | 0.236 | -13.27 | -- | -- | -15.77 | 47.19 | -45.62 | -- | -55.67 | -- |
| Nutraproducts Inc | 0.00 | -821.94k | 20.12m | 0.00 | -- | 3.36 | -- | -- | -1.31 | -1.31 | 0.00 | 0.2973 | 0.00 | -- | -- | -- | -513.70 | -1,177.23 | -740.45 | -- | -- | -- | -- | -- | -- | -385.17 | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Global Pharmatech Inc. | 3.18m | -2.24m | 20.76m | 217.00 | -- | 0.1459 | -- | 6.53 | -0.0964 | -0.0964 | 0.1367 | 0.3428 | 0.2292 | 1.59 | 3.57 | 14,649.77 | -16.44 | -- | -22.55 | -- | 46.21 | -- | -71.75 | -- | 1.62 | -9.87 | 0.2223 | -- | 32.43 | -- | -142.03 | -- | -- | -- |
| Natural Alternatives International Inc | 134.44m | -11.88m | 21.56m | 293.00 | -- | 0.3123 | -- | 0.1604 | -1.99 | -1.99 | 22.52 | 11.17 | 0.845 | 4.35 | 7.36 | 458,839.60 | -7.47 | 0.4593 | -9.15 | 0.5479 | 8.50 | 12.75 | -8.84 | 0.4296 | 1.01 | -2.56 | 0.1408 | 0.00 | 14.12 | 1.78 | -88.10 | -- | -4.46 | -- |
| Aytu Biopharma Inc | 62.64m | -24.56m | 22.86m | 82.00 | -- | 1.61 | -- | 0.365 | -3.40 | -3.39 | 5.63 | 1.32 | 0.5259 | 2.10 | 2.22 | 763,902.40 | -20.62 | -26.47 | -45.22 | -47.32 | 66.84 | 60.56 | -39.21 | -52.54 | 1.03 | 0.057 | 0.5958 | -- | 1.84 | 19.16 | -13.27 | -- | -- | -- |
| Dare Bioscience Inc | 27.69k | -17.46m | 24.29m | 21.00 | -- | 8.29 | -- | 877.27 | -1.92 | -1.92 | 0.0029 | 0.2052 | 0.0011 | -- | 0.0624 | 1,318.57 | -71.56 | -91.64 | -241.96 | -243.93 | 127.70 | -- | -63,069.55 | -1,024.05 | -- | -156.39 | 0.7177 | -- | -99.65 | -- | 86.56 | -- | -- | -- |
| Medicus Pharma Ltd | -100.00bn | -100.00bn | 26.62m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0434 | -- | -- | -- | -- | -- | -361.95 | -- | -- | -- | -- | -- | -- | -- | -- | 1.13 | -- | -- | -- | -109.90 | -- | -- | -- |
| TherapeuticsMD Inc | 2.80m | 73.00k | 27.32m | 1.00 | 378.21 | 0.9953 | 59.38 | 9.77 | 0.0062 | 0.0261 | 0.2419 | 2.37 | 0.0715 | -- | 0.8002 | 2,796,000.00 | 0.1867 | -42.65 | 0.2169 | -112.14 | -- | -- | 2.61 | -193.47 | -- | -5,240.00 | 0.00 | -- | 35.25 | -48.72 | 69.97 | -- | -- | -- |
| Kyntra Bio Inc | 8.30m | -131.13m | 30.14m | 225.00 | -- | -- | -- | 3.63 | -32.49 | 53.34 | 2.05 | -4.21 | 0.0413 | -1.47 | 0.421 | 36,880.00 | -64.00 | -39.47 | -260.98 | -61.33 | 345.69 | 90.21 | -1,548.18 | -199.02 | 3.60 | -- | 0.5269 | -- | -36.71 | -35.07 | 52.60 | -- | -45.94 | -- |
| United-Guardian Inc | 10.06m | 1.96m | 30.32m | 24.00 | 15.47 | 2.87 | 14.69 | 3.01 | 0.4266 | 0.4266 | 2.19 | 2.30 | 0.7911 | 3.82 | 7.58 | 419,180.40 | 15.41 | 26.91 | 17.85 | 31.16 | 50.60 | 54.16 | 19.48 | 26.97 | 6.16 | -- | 0.00 | 92.34 | 11.91 | -2.18 | 25.94 | -7.35 | 30.65 | -8.64 |
| SCYNEXIS Inc | 2.93m | -25.30m | 31.47m | 28.00 | -- | 0.8638 | -- | 10.73 | -0.5107 | -0.5107 | 0.0593 | 0.8683 | 0.0391 | -- | 0.5776 | 104,714.30 | -33.71 | -20.51 | -43.65 | -24.97 | 33.32 | -- | -862.89 | -64.82 | -- | -- | 0.00 | -- | -97.33 | 98.68 | -131.75 | -- | -- | -- |
| Healthy Extracts Inc | 3.59m | -1.17m | 33.74m | 2.00 | -- | 1.40 | -- | 9.40 | -0.3195 | -0.3195 | 0.9095 | 1.43 | 0.2505 | 1.42 | 140.67 | 1,794,555.00 | -8.19 | -61.21 | -9.09 | -111.60 | 52.37 | 51.30 | -32.71 | -82.01 | 0.6491 | -2.84 | 0.0421 | -- | 25.24 | 32.99 | 66.01 | -- | -- | -- |
| BioXcel Therapeutics Inc | 752.00k | -68.21m | 34.55m | 37.00 | -- | -- | -- | 45.95 | -10.41 | -10.41 | 0.1023 | -4.45 | 0.016 | 0.9718 | 501.33 | 20,324.32 | -145.62 | -76.45 | -449.90 | -88.28 | -28.19 | -- | -9,070.61 | -14,760.23 | 1.16 | -3.25 | 5.40 | -- | 64.20 | -- | 66.71 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Dare Bioscience Inc's reporting currency: US Dollar USD
7.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 454.18k | 3.18% |
| AMH Equity Ltd.as of 30 Sep 2025 | 232.37k | 1.63% |
| Geode Capital Management LLCas of 31 Dec 2025 | 118.66k | 0.83% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 65.94k | 0.46% |
| G1 Execution Services LLCas of 30 Sep 2025 | 60.22k | 0.42% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 23.52k | 0.17% |
| U.S. Bank NA (Cincinnati Ohio Investment Management)as of 31 Dec 2025 | 20.92k | 0.15% |
| UBS Securities LLCas of 31 Dec 2025 | 20.92k | 0.15% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 19.30k | 0.14% |
| Virtu Americas LLCas of 30 Sep 2025 | 17.74k | 0.12% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
